Last reviewed · How we verify
SULFADIAZINE, SILVER
At a glance
| Generic name | SULFADIAZINE, SILVER |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines (PHASE1, PHASE2)
- Location- and Frequency-Dependent Effects of Thalamic Temporal Interference Stimulation During Sleep (NA)
- Interaural Frequency and Loudness Mismatch in SSD CI Users (NA)
- Mapping the Healthcare Pathway to Multidisciplinary Assessment of 12-25 Year Olds With Somatic Symptom Disorder
- Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns (PHASE2)
- Cochlear Implantation in Children With Asymmetric Hearing Loss or Single-Sided Deafness Clinical Trial (NA)
- Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy
- Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SULFADIAZINE, SILVER CI brief — competitive landscape report
- SULFADIAZINE, SILVER updates RSS · CI watch RSS